{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-093669","form_type":"8-K","ticker":null,"cik":"0001178879","company_name":"AMICUS THERAPEUTICS, INC.","filed_at":"2023-08-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.324658+00:00","generated_at":"2026-06-11T05:59:20.232133+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Amicus Therapeutics Appoints Simon Harford as CFO; Daphne Quimi to Retire by Year End","bullets":["Simon Harford appointed CFO effective August 21, 2023; replaces Daphne Quimi who will retire at year end.","Harford receives base salary $500,000, bonus target 45% of salary, and initial equity award valued at $2.7M.","Company reiterates expectation to achieve profitability in second half of 2023.","Harford previously served as CFO of Albireo Pharma and Parexel; 30+ years healthcare finance experience."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-093669","json":"https://secwatch.observer/filing/0001104659-23-093669.json","markdown":"https://secwatch.observer/filing/0001104659-23-093669.md","text":"https://secwatch.observer/filing/0001104659-23-093669.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178879/000110465923093669/0001104659-23-093669-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178879/000110465923093669/tm2324228d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T05:59:20.232133+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"47c6538e50","claim":"Simon Harford was appointed as Chief Financial Officer at AMICUS THERAPEUTICS, INC..","evidence_excerpt":"appointed Simon Harford as the Chief Financial Officer (principal financial officer) of the Company, effective as of August 21, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178879/000110465923093669/0001104659-23-093669-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}